Aurion Biotech

Aurion's first candidate, AURN001, is for the treatment of corneal edema secondary to corneal endothelial disease, and the first clinically validated cell therapy for corneal care, having received regulatory approval from Japan's PMDA. 

As of Q2 2024, the company has completed enrollment and dosing of its Phase I / II  clinical trial in the US and Canada.